Literature DB >> 12815591

Spectrum of CLN6 mutations in variant late infantile neuronal ceroid lipofuscinosis.

Julie D Sharp1, Ruth B Wheeler, Keith A Parker, R Mark Gardiner, Ruth E Williams, Sara E Mole.   

Abstract

The neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal recessive neurodegenerative diseases of childhood. CLN6, the gene mutated in variant late infantile NCL (vLINCL), was recently cloned. We report the identification of eight further mutations in CLN6 making a total of 18 reported mutations. These mutations include missense, nonsense, small deletions or insertions, and two splice-site mutations. Ten mutations affect single amino acids, all of which are conserved across vertebrate species. Minor differences in the pattern of disease symptom evolution can be identified. One patient with a more protracted disease progression was a compound heterozygote for a missense mutation and an unidentified mutation. Fifteen CLN6 mutations occur in one or two families only, and families from the same country do not all share the same mutation. Unlike NCLs caused by mutations in CLN1, CLN3, CLN5, and CLN8, there is no major founder mutation in CLN6. However, one mutation (E72X) is significantly more common in patients from Costa Rica than two other mutations present in that same population. In addition, a 1-bp insertion (c.316insC) is associated with families from Pakistan and I154del may be common in Portugal. A group of Roma Gypsy families from the Czech Republic share two disease-associated haplotypes, one of which is also present in a Pakistani family, consistent with the proposed migration of the Roma from the Indian subcontinent 1,000 years ago. All mutations are recorded in the NCL Mutation Database together with their country of origin for use in the development of rapid screening assays to confirm diagnosis and to facilitate carrier testing appropriate to a population. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12815591     DOI: 10.1002/humu.10227

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  18 in total

Review 1.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

Review 2.  Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses.

Authors:  Sara E Mole; Ruth E Williams; Hans H Goebel
Journal:  Neurogenetics       Date:  2005-09-28       Impact factor: 2.660

3.  Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations.

Authors:  Laura Canafoglia; Isabella Gilioli; Federica Invernizzi; Vito Sofia; Valeria Fugnanesi; Michela Morbin; Luisa Chiapparini; Tiziana Granata; Simona Binelli; Vidmer Scaioli; Barbara Garavaglia; Nardo Nardocci; Samuel F Berkovic; Silvana Franceschetti
Journal:  Neurology       Date:  2015-06-26       Impact factor: 9.910

4.  Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6.

Authors:  Todor Arsov; Katherine R Smith; John Damiano; Silvana Franceschetti; Laura Canafoglia; Catherine J Bromhead; Eva Andermann; Danya F Vears; Patrick Cossette; Sulekha Rajagopalan; Alan McDougall; Vito Sofia; Michael Farrell; Umberto Aguglia; Andrea Zini; Stefano Meletti; Michela Morbin; Saul Mullen; Frederick Andermann; Sara E Mole; Melanie Bahlo; Samuel F Berkovic
Journal:  Am J Hum Genet       Date:  2011-05-05       Impact factor: 11.025

5.  Protein product of CLN6 gene responsible for variant late-onset infantile neuronal ceroid lipofuscinosis interacts with CRMP-2.

Authors:  Jared W Benedict; Amanda L Getty; Thomas M Wishart; Thomas H Gillingwater; David A Pearce
Journal:  J Neurosci Res       Date:  2009-07       Impact factor: 4.164

6.  A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3.

Authors:  Tony Frugier; Nadia L Mitchell; Imke Tammen; Peter J Houweling; Donald G Arthur; Graham W Kay; Otto P van Diggelen; Robert D Jolly; David N Palmer
Journal:  Neurobiol Dis       Date:  2007-09-29       Impact factor: 5.996

Review 7.  Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy.

Authors:  Nicola Specchio; Alessandro Ferretti; Marina Trivisano; Nicola Pietrafusa; Chiara Pepi; Costanza Calabrese; Susanna Livadiotti; Alessandra Simonetti; Paolo Rossi; Paolo Curatolo; Federico Vigevano
Journal:  Drugs       Date:  2021-01       Impact factor: 9.546

8.  Advances in the Treatment of Neuronal Ceroid Lipofuscinosis.

Authors:  Jonathan B Rosenberg; Alvin Chen; Stephen M Kaminsky; Ronald G Crystal; Dolan Sondhi
Journal:  Expert Opin Orphan Drugs       Date:  2019-11-27       Impact factor: 0.694

9.  Biometals in rare neurodegenerative disorders of childhood.

Authors:  Sarah J Parker; Jari Koistinaho; Anthony R White; Katja M Kanninen
Journal:  Front Aging Neurosci       Date:  2013-03-25       Impact factor: 5.750

10.  Clinical and genetic characterization of a cohort of 97 CLN6 patients tested at a single center.

Authors:  Corina-Marcela Rus; Thomas Weissensteiner; Catarina Pereira; Iuliana Susnea; Bright D Danquah; Galina Morales Torres; Maria Eugenia Rocha; Claudia Cozma; Deepa Saravanakumar; Sumanth Mannepalli; Krishna K Kandaswamy; Sebastiano Di Bucchianico; Ralf Zimmermann; Arndt Rolfs; Peter Bauer; Christian Beetz
Journal:  Orphanet J Rare Dis       Date:  2022-05-03       Impact factor: 4.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.